{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:18:00Z","timestamp":1769584680977,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG 11-186 (DBC)"],"award-info":[{"award-number":["RSG 11-186 (DBC)"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA090578 (DBC)"],"award-info":[{"award-number":["P50CA090578 (DBC)"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA169259 (SSK)"],"award-info":[{"award-number":["R01CA169259 (SSK)"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA17830 (SSK)"],"award-info":[{"award-number":["R21CA17830 (SSK)"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.lungcan.2018.01.002","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T13:23:53Z","timestamp":1515072233000},"page":"90-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Tumor biomarker testing in non-small-cell lung cancer: A decade of change"],"prefix":"10.1016","volume":"116","author":[{"given":"Paul A.","family":"VanderLaan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepa","family":"Rangachari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adnan","family":"Majid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihir S.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidharta P.","family":"Gangadharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Kent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle C.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark S.","family":"Huberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu S.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel B.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2018.01.002_bib0005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2014.01.013","article-title":"Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer","volume":"84","author":"VanderLaan","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.01.002_bib0010","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ctrc.2015.10.004","article-title":"Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice","volume":"4","author":"Rangachari","year":"2015","journal-title":"Cancer Treat. Commun."},{"key":"10.1016\/j.lungcan.2018.01.002_bib0015","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.jtho.2016.12.026","article-title":"Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 \u226550% expression in lung adenocarcinoma","volume":"12","author":"Rangachari","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.01.002_bib0020","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.01.002_bib0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2018.01.002_bib0030","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.01.002_bib0035","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.01.002_bib0040","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.lungcan.2013.07.013","article-title":"Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice","volume":"82","author":"Yamaguchi","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.01.002_bib0045","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.5858\/arpa.2016-0091-SA","article-title":"Biomarker testing in lung carcinoma cytology specimens: a perspective from members of the pulmonary pathology society","volume":"140","author":"Roy-Chowdhuri","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.lungcan.2018.01.002_bib0050","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1158\/2159-8290.CD-16-1337","article-title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","volume":"7","author":"Jordan","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.lungcan.2018.01.002_bib0055","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1158\/1078-0432.CCR-14-2683","article-title":"Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches","volume":"21","author":"Drilon","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2018.01.002_bib0060","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1001\/jama.2014.3741","article-title":"Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs","volume":"311","author":"Kris","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.lungcan.2018.01.002_bib0065","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.01.002_bib0070","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.jtho.2017.06.002","article-title":"Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy","volume":"12","author":"Rangachari","year":"2017","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218300023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218300023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T13:45:37Z","timestamp":1538574337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218300023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":14,"alternative-id":["S0169500218300023"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.002","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor biomarker testing in non-small-cell lung cancer: A decade of change","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}